hims & hers fda warning letter compounded semaglutide 2025 issued 25 letters to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Semaglutide Patient Safety Updates |

Compounded GLP-1 medications occupy a different regulatory category than FDA-approved brand-name drugs, and individual results vary depending on adherence, dosage, diet, activity, and individual physiology

Not sure if Wegovy is covered by your insurance plan

Cenexa Labs has no affiliation with Dr

If survodutide reaches market before retatrutide, it could provide early real-world evidence on glucagon receptor safety, which would benefit the retatrutide review process

Health care professionals may prescribe GLP-1s for people with diabetes and binge eating disorder with strong psychotherapy support, a slow dose titration and close follow-up after initiation, according to two speakers